Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%.
Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.
Research Highlights The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights.
In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion.
Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.
Key Features The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.
Key Issues Addressed • What is the current scenario of the biosimilars market in APAC, and how far will it grow? • What are the key factors driving the market, and what are the barriers that need to be resolved? • Which are the key market segments to look out for, and what are the key trends and regulatory aspects? • Who are the key market participants involved, and where do they stand? • What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market? • What is the future of the biosimilars market in Asia?
Our reports have been used by over 10K customers, including:
220 pages •
By The Business Research Company
• Jul 2018
Biologics Global Market Opportunities And Strategies By Product Type: Monoclonal Antibodies (mAbs), Therapeutic Proteins and Vaccines; By Region, By Country, With Forecast Until 2021 The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human...
The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period. The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness,...
US payers eye European biologics market with envy Biosimilars may be a roaring success in Europe but the picture in the US couldn’t be more different. Once hailed as a solution to stem the tide of soaring drug spending, in the cold light of day, the US biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle...
Report Scope: Biosimilars are replicas of the innovator biopharmaceuticals.They offer the advantage of being less expensive as compared to their expensive counterparts. The structural and manufacturing complexities associated with their development have led to extensive approval guidelines and regulations by the...
221 pages •
By The Business Research Company
• Mar 2018
The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes.Biologics products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies. These products are isolated from natural sources such as human, animal, and...
The global biosimilar market was estimated to be valued at USD 3,474.01 million in 2017, and is expected to register a CAGR of 43.85% during the forecast period of 2018-2023. North America accounted for the largest share of approximately 30% of the global market, in 2017, while Asia-Pacific region is anticipated to register the highest CAGR...